𝗠𝗙𝗡 𝗣𝗿𝗶𝗰𝗶𝗻𝗴 𝗪𝗵𝗶𝘁𝗲 𝗣𝗮𝗽𝗲𝗿 𝗳𝗿𝗼𝗺 𝗢𝘂𝗿 𝗘𝘅𝗽𝗲𝗿𝘁 𝗡𝗲𝘁𝘄𝗼𝗿𝗸

📢 Out now: MFN Pricing White Paper from our Expert Network

🤝 By bringing together national pricing and reimbursement expertise with global pricing insights, our network has produced a new publication: “US MFN and its Implications for Pharmaceutical Access”, highlighting the current developments in US pricing.

💡So far, we know that the US pricing model, GENEROUS using the Most Favored Nation (MFN) approach, references prices in Denmark, Germany, France, Italy, Switzerland, the UK, Canada and Japan. Understanding the pricing and reimbursement (P&R) landscapes in these markets is essential – which is why the white paper also provides detailed insights into national P&R systems.

And what about the GLOBE and GUARD models? Although still under development, they are included in our publication, ensuring that all aspects of MFN are comprehensively covered.

Based on national expertise from each MFN country, the white paper provides guidance for pharmaceutical companies on how they can operate effectively in this rapidly changing environment.

MFN poses a significant challenge, but it highlights the importance of a global perspective and an well-functioning network.